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!"#$%&'$()*+,-./0,1(The objective of this selective EBM review is to determine whether or not 
anti depressants are effective in the treatment of depressed patients who do not seek 
psychotherapy. 
STUDY DESIGN: Review of all English language primary randomized controlled trials 
published from 2000-2009.   
DATA SOURCES: Three randomized controlled trials were found using OVID, Medline, 
EbscoHost, Pubmed, and Cochrane databases.  
OUTCOMES MEASURED: The three trials measured the change in the severity of 
depression symptoms using different outcomes: The Montgomery Asburg Depression 
Scale, Hamilton Depression Rating Scale, and Hopkins Symptom Checklist Depression 
Scale.   
RESULTS: Hermens et al. found that the use of usual care and paroxetine is no more 
effective than usual care at fifty-two weeks. Barrett et al. found that paroxetine is no 
more effective than placebo in the treatment of depression at eleven weeks. Williams et 
al. found that paroxetine is more effective than placebo in decreasing depressive 
symptoms, in older adults, at eleven weeks.  
CONCLUSIONS: The work of Hermens and Barrett demonstrated that paroxetine is no 
more effective than usual care in the treatment of depression within the general 
population. Williams RCT’s demonstrates that paroxetine may be effective in the 
treatment of depression in older adults.  
KEY WORDS: depression, anti depressants, treatment + depression (
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Depression is a serious mental illness characterized by a depressed mood in 
conjunction with fatigue, changes in sleep patterns, changes in eating patterns, irritability, 
and the inability to enjoy things that one previously enjoyed. Because depression is a 
spectrum disorder that ranges from dysthymia to major depression, the treatments are 
numerous and diverse. It can include psychotherapy, medication, electroconvulsive 
therapy, or any combination. The first line treatment for people with depression involves 
antidepressant therapy, most commonly in the form of selective serotonin reuptake 
inhibitors (SSRI’s), together with outpatient psychotherapy4. It is not currently known 
whether antidepressant therapy is effective without concurrent psychotherapy. This paper 
analyzes three randomized controlled studies to determine the effectiveness of 
antidepressants when not in conjunction with psychotherapy.  
Despite great progress in the treatment and diagnosis of depression, it still 
continues to be incredibly common within the general population. The lifetime 
prevalence of major depression is 7-12% and 20-25% in men and women respectively 2, 
which in recent years has accounted for up to 9.7 million office visits5. Among patients 
with health related comorbidities the prevalence is believed to be as high as 20-40%5. 
The yearly cost of depression in the United States is projected to be as high as twenty six 
billion dollars; with indirect costs as high as fifty billion dollars5.  
Due to time constraints, managed care, and the stigma attached with 
psychotherapy, physician assistants will find themselves with patients for whom 
psychotherapy is not an option.  Keeping in mind the prevalence, costs, morbidity, and 
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mortality associated with depression, the need for determining the effectiveness of 
antidepressants as a sole treatment becomes apparent.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not 
antidepressants are effective in the treatment of depressed patients who do not seek 
psychotherapy. 
METHODS 
In order for studies to be included for review, all patients had to be over the age of 
18, in the outpatient setting and also have a clinical diagnosis of depression using the 
Diagnostic and Statistic Manual of Mental Disorders (DSM). The intervention for all 
studies was oral Paroxetine and the comparison group was no treatment other than usual 
care or a placebo pill. The outcomes that were measured in each study attempted to 
capture the change in depressive symptoms. The three studied included are Randomized 
Controlled Trials (RCT’s).  
Peer reviewed journals written in the English language were searched using 
OVID, Medline, EbscoHost, Pubmed, and Cochrane databases between December 2010 
and January of 2011. The key words used in searches were depression, antidepressants, 
and treatment+ depression. The inclusion criteria for each study required that it be an 
RCT with Patient Oriented Evidence that Matters (POEM) and have been completed in 
the past 10 years. The exclusion criteria were studies with patients under 18, patients 
currently on antidepressants, and those having previous issues with substance abuse. All 
searches were conducted by the author and Stephanie Ferretti of the Philadelphia College 
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of Osteopathic Medicine Library.  All studies were published. The statistics reported 
include p value, relative risk ratio (RRR), and numbers needed to treat (NNT).  
A. Table 1 - Demographics & Characteristics of included studies 
 
OUTCOMES MEASURED: 
  The study performed by Hermens et al. took place in the Netherlands with 
patients recruited by primary care physicians. Upon identification of possible patients, 
research assistants conducted baseline interviews in which the patient received an 
explanation of the study and then informed consent was obtained. The patients were then 
randomized into usual care plus antidepressants or usual care alone. At the conclusion of 
the study the patient’s depressive symptoms, as measured by The Montgomery Asberg 
Depression Rating Scale, were compared to their symptoms at intake. 
Study Type # 
patients 
Age 
(yrs) 
Inclusion Criteria W/D Interventio
ns 
Barrett, 
2001 (1) 
RCT 241 18-59 3/9 DSM-III-R 
symptoms for major 
depression for at least 4 
weeks, DSM-III-R 
criteria  for dysthymia or 
minor depression,  >10 
on HDRS 
20 Paroxetine 
Hermens, 
2007 (3) 
RCT 181 18+ 3-6/9 DSM-IV symptoms 
of depression, significant 
distress/impairment, 
symptoms daily for 2 
weeks 
21 Paroxetine 
Williams, 
2000 (5) 
RCT 415 60+ Minor 
depression/dysthymia 
diagnosed by DSM-IIIR, 
HDRS >9, 3-4 symptoms 
for at least 4 weeks 
65 Paroxetine 
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 The study performed by Barrett et al. took place in New Hampshire and 
Washington with patients recruited by primary care physicians at these two sites. Patients 
who met all criteria were consented and randomized to paroxetine, placebo, or Problem-
Solving Treatment for Primary Care. At the conclusion of the study the patients’ 
depressive symptoms, as measured by the Hamilton Depression Rating Scale, were 
compared to their symptoms at intake.  
 The study performed by Williams et al. took place at four geographically and 
clinically diverse sites (location unspecified) with patients recruited through referral from 
various primary care clinics. Patients who met all criteria were consented and randomized 
to placebo, paroxetine, or Problem-Solving Treatment for Primary Care. At the 
conclusion of the study the patients’ depressive symptoms were measured using the 20- 
item Hopkins Symptom Checklist Depression Scale.  
RESULTS:  
 The study by Hermens et al. from 2007 used patients over the age of 18 with a 
diagnosis of minor or mild-major depression.  The test group was given 20 mg/day of 
oral paroxetine and usual care for three months. The control group received only usual 
care for three months. Patients in the test group could increase their dose of paroxetine to 
40mg a day, if at 4 weeks their clinical response was poor. The study was conducted for a 
total of 52 weeks. Hermens et al. reported that greater than 25% of patients were not 
treated according to protocol. Table 2 shows that there was a 14.7 point decrease in the 
Montgomery Asberg Depression Rating Scale score from baseline at 52 weeks with usual 
care and paroxetine. For patients with usual care only, there was a decrease of 12.6 
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points. The CI at 95% is wide at -6.2;1.9 with a standard deviation of 24.2 The data 
presented is continuous and cannot be converted to dichotomous data because the author 
does not include individual scores for the patients, only the average of all test subjects. 
This study fails to show that usual care and paroxetine are any more effective than usual 
care at 52 weeks.  
Table 3: The Effect of Antidepressants on Montgomery Asberg Depression Rating Scales 
Hermens et al.  
Outcomes 
measured 
Usual Care + 
Paroxetine 
Usual Care Mean difference Confidence 
interval at 
95% 
Change in 
MADRS* 
from baseline 
-14.8 -12.7 2.1 -6.2; 1.9 
*Montgomery Asberg Depression Rating Scales 
  The study by Barrett et al. from 2001 used patients aged 18-59 with minor 
depression or dysthymia.  The test group received oral paroxetine that was started at 
10mg/day and increased to 20mg/day at week 2. At week 4 or 6 the dose could be further 
increased to 30mg per day and at week 6 or 8 to 40mg if there was limited clinical 
improvement. The control group received a placebo that was titrated in the same fashion. 
As is shown in table 4, 60.7% of those who received paroxetine and 65.6% of those who 
received placebo, achieved remission as defined by a score of 6 or less on the Hamilton 
Depression Rating Scale (p= .906). The relative benefit increase was found to be -0.0747, 
absolute benefit increase -4.90, and number needed to treat= -20.0.  This study fails to 
show that paroxetine is any more effective than placebo in the treatment of depression at 
11 weeks.  
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Table 4: The Effect of Antidepressants on Rate of Remission as Defined by Hamilton 
Depression Rating Scale 
Barrett et al.  
Outcomes 
measured 
Paroxetine Placebo p RBI ABI NNT 
Remission 
Rate (%) 
60.7 65.6 -0.906 -0.0747 -4.90 -20.0 
 
The study by Williams et al. from 2000 used patients with a clinical diagnosis of 
dysthymia and minor depression over the age of 60. Oral paroxetine was administered to 
their test group which was started at 10mg/day and then subsequently increased to 
20mg/day at week 2. At week 4 or 6 the dose could be further increased to 30mg per day 
and at week 6 or 8 to 40mg if clinical improvement was limited. The control group 
received placebo that was titrated in an identical fashion. As is shown in table 5, 53.1% 
of those who received paroxetine and 49.1% of those who received placebo achieved 
remission as defined by a score of 6 or less on the Hamilton Depression Rating Scale (p= 
0.004). The relative benefit increase was found to be 0.0815, absolute benefit increase 4, 
and number needed to treat= 25.  This study shows that paroxetine is more effective than 
placebo in the treatment of depression at 11 weeks. 
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Table 5: The Effect of Antidepressants on Rate of Remission as Defined by the Hopkins 
Symptom Checklist Depression Scale 
Williams et al.  
Outcomes 
measured 
Paroxetine Placebo p RBI ABI NNT 
Remission 
Rate (%) 
53.1 49.1 -0.906 -0.0815 4 25 
 
In the study by Williams at al. 9.7% of patients taking paroxetine dropped out due 
to adverse side effects whereas 5.7% of those taking placebo dropped out due to side 
effects. NNH was calculated to be 27. This is the only study, of the three, to give data on 
the patients who dropped out as a result of adverse side effects. None of the studies give 
any indication as to the side effects or adverse reactions patients experienced.  
Table 5: Harms Associated With Treatment 
Study RRI ARI NNH 
Barrett, 2001 (1)    
Hermens, 2007 (3)    
Williams, 2000 (5) .64 3.4 27 
 
DISCUSSION: 
There was a great degree of incongruence between the three studies included for 
review. The most important being that the only study to show paroxetine as an effective 
treatment only included patients over the age of sixty. This leaves questions as to whether 
paroxetine is an effective treatment in this specific population. Other discrepancies 
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between the studies include differences in the length of treatment as well as differences in 
disease severity of participants.  
Although the efficacy of selective serotonin reuptake inhibitors (SSRIs) as 
treatment for depression is questionable, they have long been used as part of the 
treatment in numerous other conditions including panic disorder, obsessive compulsive 
disorder, social phobia, post traumatic stress disorder, and premenstrual dysmorphic 
disorder. None of the included studies disclosed the cause of patient drop out as a result 
of adverse side effects, but it is apparent that SSRIs are not without side effects. Current 
black box labeling of SSRIs warn of an increased risk of suicide in patients with major 
depressive disorders, during the first two months of treatment. In addition, patients taking 
SSRIs are at risk for serotonin syndrome, which is a life threatening disorder 
characterized by excess serotonin that manifests itself as restlessness, hallucinations, loss 
of coordination, fast heart beat, rapid changes in blood pressure, increased body 
temperature, overactive reflexes, nausea, vomiting, and diarrhea. Some of the more minor 
and yet more common side effects include anxiety, constipation, insomnia, erectile 
dysfunction, and decreased libido4.  
CONCLUSION: 
 Using the three studies included for systematic review, it cannot be concluded that 
antidepressants, as monotherapy, are an effective treatment for depression in the general 
population. However, based on the results of the study by Williams et al, antidepressants 
may be effective in adults over the age of 60 with a diagnosis of depression.  
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 Given the profound economic and social impact of depression, it would be 
beneficial to further study the efficacy of antidepressants as monotherapy in specific 
subpopulations including teens and middle-aged adults. It would also be advantageous to 
closely study their effect on the specific clinical presentations of depression, namely 
dysthymia, mild depression, and major depression. Lastly, it would be helpful to know 
the effectiveness of antidepressants at distinct time intervals within a depressive episode.  
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